跳至主要内容
临床试验/NCT04374084
NCT04374084Unknown不适用

Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial

Guang'anmen Hospital of China Academy of Chinese Medical Sciences1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年5月10日最近更新:
适应症

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
The proportion of responder at week 4

研究概览

简要总结

This trial is designed to evaluate the efficacy and safety of moxibustion plus cupping in the convalescence of COVID-19.

详细描述

Moxibustion plus cupping may be effective and safe for convalescent patients with COVID-19, but evidence is limited. The randomized clinical trial may help to provide evidence-based factors for improving the patients' symptoms in the convalescence of COVID-19.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of the convalescence of COVID-19 (defined by the Chinese Guideline for COVID-19 in 2020 Trial Version 7).
  • 18-70 years old;
  • chest tightness/fatigue/shortness of breath/cough, with at least 2 of the above symptoms and the average VAS score (last 48 hours) ≥ 40 points;
  • Volunteers with informed consent;

排除标准

  • Surgery in the lung that affects lung function;
  • Rely on mechanical ventilation to maintain lung function;
  • Chronic lung diseases affecting lung function;
  • Diseases affecting heart function;
  • Severe basic diseases;
  • Resting heart rate > 120/min, systolic blood pressure > 180mmHg, diastolic blood pressure > 100mmHg;
  • Unstable angina or myocardial infarction in the past 1 month;
  • Severe obesity (BMI>30kg/m2);
  • Allergic constitution;
  • Pregnant or lactating women;
  • Disabled patients;
  • Mentally ill Patients;
  • Participating in other clinical trials;
  • Poor compliance or other complicate conditions according to the researchers.

结局指标

主要结局

The proportion of responder at week 4

时间窗: baseline, week 4

The responder is defined as the participants with ≥ 50% average VAS decrease of chest tightness and fatigue compared with baseline. The VAS ranges from 0 to 100.

次要结局

  • The change of the walking distance of six-minute-walking test from baseline(baseline, week 4, week 8)
  • The change of the lowest oxygen saturation of six-minute-walking test from baseline(baseline, week 4, week 8)
  • The proportion of patients in recovery of pulmonary function at week 4(baseline, week 4)
  • The proportion of responder at week 8(baseline, week 8)
  • The change in the average VAS score of main symptoms from baseline(baseline, week 4, week 8)
  • The change in the average VAS score of other symptoms from baseline(baseline, week 4, week 8)
  • The change in mean frequency of diarrhea and spontaneous bowel movements from baseline(baseline, week 4, week 8)
  • The proportion of participants with ≥50%/75% improvement of VAS from baseline(baseline, week 4, week 8)
  • The change of the SDS score from baseline(baseline, week 4, week 8)
  • The change in the severity VAS score of main symptoms from baseline(baseline, week 4, week 8)
  • The proportion of patients whose lung CT return to normal at week 4(baseline, week 4)
  • The change of the SAS score from baseline(baseline, week 4, week 8)
  • The change of the WHO QOL-BREF score from baseline(baseline, week 4, week 8)
  • The change of the blood CRP/LYMPH#/NEUT% value from baseline(baseline, week 4)
  • subtype analysis(baseline, week 4)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiaopin Wang

Secretary of Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

研究点 (1)

Loading locations...

相似试验